SuperArray Bioscience Licenses PCR and RT-PCR Patents from Applied Biosystems
News Jun 05, 2007
SuperArray Bioscience Corporation has announced that it has entered into a PCR (polymerase chain reaction) license agreement with Applied Biosystems, an Applera Corporation business. Under the agreement, SuperArray Bioscience Corporation will develop, manufacture and distribute worldwide new Real-Time PCR and PCR-related reagents.
The agreement enables SuperArray Bioscience Corporation to offer optimized reagents and kits for PCR and Real-Time PCR that utilize SYBR Green and probe- based methods.
The agreement also allows SuperArray Bioscience Corporation to develop Real-Time PCR reagent products and technologies and to pass on rights to end-user customers in the research field for the performance of Real-Time PCR.
"We are excited to create Real-time PCR-based pathway and gene analysis assays using the technologies from Applied Biosystems," said Dr Li Shen, President of SuperArray Bioscience Inc.
"The combination of highest quality qRT-PCR assays and complete coverage of every gene in human, rat and mouse genome at SuperArray will help biomedical researchers unveil important biomolecular networks of genes. The unique capability of SuperArray to examine pathways in an integrated approach will greatly expand the application of real-time PCR in drug discovery and biomedical research."
The foundational patents covering the PCR process expired in the U.S. in March of 2005 and Europe in March 2006, but several other patents related to PCR remain in force. These surviving patents that have been licensed to SuperArray Bioscience Corporation on a non-exclusive basis cover, for example, enzyme compositions and certain Real-Time PCR methods and kits.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.